Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of ocrelizumab in progressive multiple sclerosis
NL-OMON56383Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Roche. Primary endpoint: Effectiveness of ocrelizumab in progressive multiple sclerosis. Started Jul 2018; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON56383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56383.